9 research outputs found
Propylthiouracil-Induced Acute Liver Failure: Role of Liver Transplantation
Propylthiouracil- (PTU-) induced hepatotoxicity is rare but potentially lethal with a spectrum of liver injury ranging from asymptomatic elevation of transaminases to fulminant hepatic failure and death. We describe two cases of acute hepatic failure due to PTU that required liver transplantation. Differences in the clinical presentation, histological characteristics, and posttransplant management are described as well as alternative therapeutic options. Frequent monitoring for PTU-induced hepatic dysfunction is strongly advised because timely discontinuation of this drug and implementation of noninvasive therapeutic interventions may prevent progression to liver failure or even death
Recommended from our members
P0878 : First ribavirin-free sofosbuvir and simeprevir treatment of Hepatitis C genotype 1 patients with severe renal impairment (GFR <30 ml/min or dialysis)
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
Summary
Background
Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy.
Aim
To assess the correlation between perianal fistula healing and trough levels of infliximab.
Methods
In this crossâsectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24Â weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, antiâinfliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing.
Results
117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4.4Â ÎŒg/mL, respectively (PÂ <Â 0.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The AUC for the association between fistula healing and infliximab levels was 0.82 (PÂ <Â 0.0001), while the AUC for the association of infliximab levels and fistula closure was 0.69 (PÂ =Â 0.014). Patients with antiâinfliximab antibodies had a lower chance of achieving fistula healing (OR: 0.04 [95%CI: 0.005â0.3], PÂ <Â 0.001).
Conclusions
There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels â„10.1Â mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treatâtoâtarget strategy.
Linked ContentThis article is linked to Mitrev et al paper. To view this article visit https://doi.org/10.1111/apt.14020
Characterization of Immune Phenotypes as Predictive Biomarkers for Response to Vedolizumab
An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : a case series
Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to alpha 4 beta 7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the alpha 4 beta 7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of alpha 4 beta 7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism